ATMA CENA
All articles

A Next-Generation Psychedelic Compound Reports Its First Phase 3 Results: What Helus Pharma's APPROACH Trial Means for Canadian Practitioners

5 min read
A calm, daylit clinic waiting area with sage-green armchairs, a round wooden table and potted plants.

On Monday, November 16, 2026, Helus Pharma announced topline results from APPROACH, a Phase 3 trial of HLP003, a modified classic psychedelic compound, given as an add-on to antidepressant medication in adults with major depressive disorder. According to the company, the trial met its primary endpoint at week 6 and its key secondary endpoint at week 12. It is the first Phase 3 readout for a next-generation, chemically modified psychedelic compound, and the first for a classic psychedelic given as an add-on to standard antidepressants in major depressive disorder.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334.

For Canadian practitioners there is an extra reason to pay attention. Helus Pharma is the company formerly known as Cybin, based in Toronto and New York, and the investigator quoted in the announcement is Roger S. McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto. As a Leader in Psychedelic News, ATMA CENA tracks every late-stage readout in this field, and this one marks the point where a Canadian-built programme enters the body of late-stage data that regulators will weigh.

What HLP003 is, and how the trial was run

HLP003, previously called CYB003, is a deuterated compound: a classic psychedelic molecule with deuterium atoms substituted at specific positions to change how the body processes it. Helus describes it as a novel serotonergic agonist, and it holds FDA Breakthrough Therapy Designation as an adjunctive treatment in major depressive disorder.

APPROACH was a multicentre, randomized, double-blind, placebo-controlled trial. Participants were adults with moderate to severe major depressive disorder, defined by a Montgomery-Ã…sberg Depression Rating Scale (MADRS) score of at least 24, who continued their existing antidepressant at a stable dose throughout. According to the trial design presented at Psych Congress in September and reported by HCPLive, participants received two doses of HLP003 16 mg or placebo, one on day 1 and one on day 22. The intent-to-treat analysis included 222 people, with baseline MADRS scores of 32.7 in the HLP003 group and 33.8 in the placebo group.

What the company reported

On the primary endpoint, the least-squares mean change in MADRS at week 6 was −19.5 points with HLP003 versus −11.9 with placebo, a difference of −7.6 points (p<0.0001) and an effect size of 0.653. At week 12, the key secondary endpoint, the difference was −7.0 points (−16.9 versus −9.9), with an effect size of 0.581. A difference of −5.0 points was reported on day 2, the day after the first dose.

These are the sponsor's topline figures, as reported by Psychiatric Times. They have not been peer reviewed, and the full dataset has not yet been presented.

Ready to offer this in your practice?

Talk with a program advisor about ATMA CENA's training pathways and whether they fit your practice.

The safety question

Helus says HLP003 was "generally well tolerated," that most adverse events were mild to moderate, transient and largely confined to the dosing day, and that no new safety signals were identified. The company also reports three treatment-related serious adverse events in the HLP003 group without describing them. STAT News, covering the announcement the same day, wrote that "a number of serious adverse events in the study raised questions about the safety of the treatment."

Until the full dataset is presented, practitioners should hold both facts at once: a statistically significant result on the primary endpoint and an unresolved safety picture. The nature of those three events, the discontinuation rate, suicidality measures and any cardiovascular findings all matter for how a two-dose regimen might eventually be delivered, and none of them is public yet.

Expand what you can offer your patients

Our training prepares regulated professionals to deliver psychedelic-assisted therapy safely and confidently.

What comes next

APPROACH is the first of three studies in the PARADIGM programme. EMBRACE, a second pivotal trial of roughly 330 participants comparing 16 mg, 8 mg and placebo, is ongoing, with topline results expected in the fourth quarter of 2027. EXTEND, a long-term extension study, will follow participants from both trials to examine durability and the possible role of re-dosing. The company has pointed toward a potential New Drug Application to the FDA in 2028, so any U.S. decision is still some years away, and an FDA decision is not a Health Canada decision.

One week earlier, Compass Pathways completed its own FDA application for COMP360, covered on this blog on November 10. The two programmes differ in molecule, population and design, and the FDA now has a growing body of late-stage psychedelic data in front of it.

Join a national network of trained clinicians

Explore ATMA CENA's certification pathways and the CoCare clinic network with a program advisor.

What it means for Canadian practitioners

Nothing changes for Canadian clinical practice today. HLP003 remains investigational, and access to classic psychedelics in Canada outside clinical trials remains narrow and tightly restricted under federal controls. But the direction of travel is clearer. If a second trial confirms this result and the safety data hold up, nurses, physicians, psychologists and therapists may be asked to prepare, support and integrate patients through supervised dosing sessions layered on top of ordinary antidepressant care, within a model that regulators, not advocates, will define.

That is a skill set, not a credential, and it takes time to build. ATMA CENA's Advanced Pathways, which include the Psychedelic Therapy Foundations course as part one, are designed for exactly this transition. If you would like to talk through which pathway fits your practice, you can book a call with a program advisor or explore the training options.

Sources

  1. Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder. Helus Pharma Inc. / GlobeNewswire, 2026.
  2. Helus' psychedelic drug improved depression in study but faces safety questions. STAT News, 2026.
  3. Positive Phase 3 Results: HLP003 as Adjunctive Treatment for Major Depressive Disorder. Psychiatric Times, 2026.
  4. Phase 3 PARADIGM: HLP003 for Adjunctive MDD Use. HCPLive, 2026.
  5. Cybin alters state to become Helus Pharma for Nasdaq trip. Fierce Biotech, 2026.

Get trained in psychedelic-assisted therapy

Explore ATMA CENA locations across Canada.